CN113197864A - Tylosin tartrate soluble powder and preparation method thereof - Google Patents
Tylosin tartrate soluble powder and preparation method thereof Download PDFInfo
- Publication number
- CN113197864A CN113197864A CN202110496761.0A CN202110496761A CN113197864A CN 113197864 A CN113197864 A CN 113197864A CN 202110496761 A CN202110496761 A CN 202110496761A CN 113197864 A CN113197864 A CN 113197864A
- Authority
- CN
- China
- Prior art keywords
- tylosin tartrate
- soluble powder
- beta
- hydroxypropyl
- cyclodextrin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses tylosin tartrate soluble powder and a preparation method thereof, and the tylosin tartrate soluble powder mainly comprises the following raw materials: 20-50 parts of tylosin tartrate, 50-80 parts of hydroxypropyl-beta-cyclodextrin, 0.1-1 part of pH regulator and pure water. The method has simple and efficient process, and the prepared tylosin tartrate soluble powder has increased solubility and improved stability, can cover the unpleasant odor of the medicament and reduce the irritation of the medicament, thereby improving the bioavailability of the medicament, enhancing the medicament effect and relieving side effects. By controlling the particle size of the material in the spray drying process, the flowability of the product is improved, and the method is more suitable for being used in a culture terminal.
Description
Technical Field
The invention relates to the technical field of animal medicine, in particular to tylosin tartrate soluble powder and a preparation method thereof.
Background
The solubility and the stability of the traditional tylosin tartrate soluble powder are poor, the bad smell of the medicine cannot be covered, and the tylosin tartrate soluble powder has certain irritation, so that the side effect is increased, and the tylosin tartrate soluble powder is not beneficial to the use of a culture terminal.
Disclosure of Invention
The invention aims to provide tylosin tartrate soluble powder and a preparation method thereof aiming at the defects and shortcomings of the prior art.
In order to achieve the purpose, the invention adopts the technical scheme that: the tylosin tartrate soluble powder is characterized by mainly comprising the following raw materials: 20-50 parts of tylosin tartrate, 50-80 parts of hydroxypropyl-beta-cyclodextrin, 0.1-1 part of pH regulator and pure water.
The preparation method of the tylosin tartrate soluble powder is characterized by comprising the following steps:
s1, weighing hydroxypropyl-beta-cyclodextrin, dissolving at normal temperature, wherein the ratio of hydroxypropyl-beta-cyclodextrin to pure water is 1-2:5-8W/V, and obtaining hydroxypropyl-beta-cyclodextrin water solution;
s2, weighing the tylosin tartrate according to the proportion, and dissolving the tylosin tartrate in the hydroxypropyl-beta-cyclodextrin aqueous solution;
s3, embedding at normal temperature, and stirring for 1-2h to obtain a solution;
s4, spray drying the prepared solution to obtain tylosin tartrate soluble powder, wherein the particle size of the tylosin tartrate soluble powder is controlled to be 150-200 mu m in the spray drying process.
The invention has the beneficial effects that:
the method has simple and efficient process, and the prepared tylosin tartrate soluble powder has increased solubility and improved stability, can cover the unpleasant odor of the medicament and reduce the irritation of the medicament, thereby improving the bioavailability of the medicament, enhancing the medicament effect and relieving side effects. By controlling the particle size of the material in the spray drying process, the flowability of the product is improved, and the method is more suitable for being used in a culture terminal.
Detailed Description
The following examples further illustrate the invention.
In order to make the objects, technical solutions and advantages of the present invention more apparent, the present invention is further described in detail with reference to the following embodiments. It should be understood that the detailed description and specific examples, while indicating the invention, are intended for purposes of illustration only and are not intended to limit the scope of the invention.
Example 1
A preparation method of tylosin tartrate soluble powder comprises the following steps:
s1, weighing 50 parts of hydroxypropyl-beta-cyclodextrin, dissolving at normal temperature, wherein the ratio of the hydroxypropyl-beta-cyclodextrin to pure water is 1:5W/V, and obtaining a hydroxypropyl-beta-cyclodextrin aqueous solution;
s2, weighing 20 parts of tylosin tartrate, and dissolving the tylosin tartrate in the hydroxypropyl-beta-cyclodextrin aqueous solution;
s3, embedding at normal temperature, and stirring for 1h to obtain a solution;
s4, spray drying the prepared solution to obtain the tylosin tartrate soluble powder. The particle size of tylosin tartrate soluble powder is controlled to be 150-200 mu m in the spray drying process.
Example 2
A preparation method of tylosin tartrate soluble powder comprises the following steps:
s1, weighing 80 parts of hydroxypropyl-beta-cyclodextrin, dissolving at normal temperature, wherein the ratio of hydroxypropyl-beta-cyclodextrin to pure water is 2:8W/V, and obtaining a hydroxypropyl-beta-cyclodextrin aqueous solution;
s2, weighing 50 parts of tylosin tartrate, and dissolving the 50 parts of tylosin tartrate in the hydroxypropyl-beta-cyclodextrin aqueous solution;
s3, embedding at normal temperature, and stirring for 2h to obtain a solution;
s4, spray drying the prepared solution to obtain the tylosin tartrate soluble powder. The particle size of tylosin tartrate soluble powder is controlled to be 150-200 mu m in the spray drying process.
Example 3
A preparation method of tylosin tartrate soluble powder comprises the following steps:
s1, weighing 70 parts of hydroxypropyl-beta-cyclodextrin, dissolving at normal temperature, wherein the ratio of hydroxypropyl-beta-cyclodextrin to pure water is 2:7W/V, and obtaining a hydroxypropyl-beta-cyclodextrin aqueous solution;
s2, weighing 40 parts of tylosin tartrate, and dissolving the tylosin tartrate in the hydroxypropyl-beta-cyclodextrin aqueous solution;
s3, embedding at normal temperature, and stirring for 1.5h to obtain a solution;
s4, spray drying the prepared solution to obtain the tylosin tartrate soluble powder. The particle size of tylosin tartrate soluble powder is controlled to be 150-200 mu m in the spray drying process.
Comparison of solubility before and after modification of tylosin tartrate:
(1) comparison of dissolution effects of 25% tylosin tartrate before and after improvement:
(2) the dissolution effects of the improved 25% tylosin tartrate with different dissolution concentrations are compared:
as can be seen from the above table, the improved tylosin tartrate of the present invention is superior to the traditional improved strong tylosin tartrate.
The above description is only for the purpose of illustrating the technical solutions of the present invention and not for the purpose of limiting the same, and other modifications or equivalent substitutions made by those skilled in the art to the technical solutions of the present invention should be covered within the scope of the claims of the present invention without departing from the spirit and scope of the technical solutions of the present invention.
Claims (2)
1. The tylosin tartrate soluble powder is characterized by mainly comprising the following raw materials: 20-50 parts of tylosin tartrate, 50-80 parts of hydroxypropyl-beta-cyclodextrin, 0.1-1 part of pH regulator and pure water.
2. A method for preparing the tylosin tartrate soluble powder according to claim 1, comprising the steps of:
s1, weighing hydroxypropyl-beta-cyclodextrin, dissolving at normal temperature, wherein the ratio of hydroxypropyl-beta-cyclodextrin to pure water is 1-2:5-8W/V, and obtaining hydroxypropyl-beta-cyclodextrin water solution;
s2, weighing the tylosin tartrate according to the proportion, and dissolving the tylosin tartrate in the hydroxypropyl-beta-cyclodextrin aqueous solution;
s3, embedding at normal temperature, and stirring for 1-2h to obtain a solution;
s4, spray drying the prepared solution to obtain tylosin tartrate soluble powder, wherein the particle size of the tylosin tartrate soluble powder is controlled to be 150-200 mu m in the spray drying process.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110496761.0A CN113197864A (en) | 2021-05-07 | 2021-05-07 | Tylosin tartrate soluble powder and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110496761.0A CN113197864A (en) | 2021-05-07 | 2021-05-07 | Tylosin tartrate soluble powder and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113197864A true CN113197864A (en) | 2021-08-03 |
Family
ID=77029309
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110496761.0A Pending CN113197864A (en) | 2021-05-07 | 2021-05-07 | Tylosin tartrate soluble powder and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113197864A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114642641A (en) * | 2022-05-24 | 2022-06-21 | 山东国邦药业有限公司 | Tylosin tartrate water-soluble granules and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107213470A (en) * | 2017-06-01 | 2017-09-29 | 中牧南京动物药业有限公司 | Ten thousand rhzomorph soluble powders of tartaric acid Thailand and preparation method thereof |
-
2021
- 2021-05-07 CN CN202110496761.0A patent/CN113197864A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107213470A (en) * | 2017-06-01 | 2017-09-29 | 中牧南京动物药业有限公司 | Ten thousand rhzomorph soluble powders of tartaric acid Thailand and preparation method thereof |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114642641A (en) * | 2022-05-24 | 2022-06-21 | 山东国邦药业有限公司 | Tylosin tartrate water-soluble granules and preparation method thereof |
| CN114642641B (en) * | 2022-05-24 | 2022-07-26 | 山东国邦药业有限公司 | Tylosin tartrate water-soluble granules and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106106522B (en) | A kind of nano zine oxide-load silver chitosan compound anti-bacteria agent and preparation method thereof | |
| CN112624659B (en) | Composite plant protein foaming agent and preparation method thereof | |
| CN113197864A (en) | Tylosin tartrate soluble powder and preparation method thereof | |
| CN100448371C (en) | Micro capsule of nano beef essence and its preparation method | |
| CN105147620A (en) | Erythromycin thiocyanate soluble powder and preparation method thereof | |
| CN104857517A (en) | Enzalutamide soft capsule and preparation method thereof | |
| CN112190551A (en) | Florfenicol soluble powder and preparation method thereof | |
| CN106187798B (en) | A kind of chelated calcium preparation method of amino acid nanometer | |
| US20220105045A1 (en) | Pullulan empty hard capsule and preparation method therefor | |
| CN112979503A (en) | Preparation method of carbasalate calcium | |
| CN106176769B (en) | Long-acting veterinary Ursocycline injection and preparation method thereof | |
| CN107057250A (en) | A kind of environment-friendly PVC ornament materials | |
| CN115300461A (en) | Florfenicol soluble powder and preparation method thereof | |
| CN115844849A (en) | Cellulose plant soft capsule and its preparation method | |
| CN104546788B (en) | A kind of preparation method of Simvastatin Tablets | |
| CN113694847A (en) | Vitamin B12Preparation method of microcapsule tablet | |
| CN113425686A (en) | Dimetridazole soluble powder and preparation method thereof | |
| CN107033300A (en) | A kind of agricultural water-loss reducer and preparation method with highly effective water-keeping performance | |
| CN106700092A (en) | Microwave-assisted method for preparing silver fulvate | |
| WO2020093978A1 (en) | Organic nutrient type potassium sulfate dissolution accelerator, preparation therefor and use thereof | |
| CN109457515A (en) | A kind of preparation method of velvet apple fabric digit printing thickener | |
| CN113563492B (en) | Molecular type low-ester copper pectin and preparation method thereof | |
| CN113750067B (en) | Preparation process of levofloxacin tablets | |
| CN112336698A (en) | Rapidly disintegrating vaginal soft capsule composition and preparation method thereof | |
| CN105168179B (en) | A kind of clopidol sustained release microparticle preparation and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210803 |
|
| RJ01 | Rejection of invention patent application after publication |